Abiopharma

New Form 6-K - Nanobiotix S.A. Filed: 2025-07-02 AccNo: 0001628280-25-033844 Size: 1 MB

Qiagen N.V. - QIAGEN announces adjustment of conversion price under its US$500,000,000 Convertible Bonds due 2027

Qiagen N.V. - QIAGEN announces adjustment of conversion price under its US$500,000,000 Convertible Bonds due 2031

New Form SCHEDULE 13G - Inmune Bio, Inc. Filed: 2025-07-02 AccNo: 0001649553-25-000121 Size: 15 KB

Auxly Announces Results of Annual General Meeting of Shareholders

Intuitive’s da Vinci 5 Surgical System Receives CE Mark

New Form 8-K - Veradigm Inc. Filed: 2025-07-02 AccNo: 0000950170-25-092569 Size: 144 KB Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV

New Form 6-K - Inspira Technologies OXY B.H.N. Ltd Filed: 2025-07-02 AccNo: 0001213900-25-060734 Size: 32 KB

Inspira Technologies Secures $22.5 Million Purchase Order, Launches Full Revenue Execution Phase

VYNE Therapeutics Updates for 07/02/2025

Cyclacel Pharmaceuticals Announces Stock Split

New Form 8-K - Sonnet BioTherapeutics Holdings, Inc. Filed: 2025-07-02 AccNo: 0001641172-25-017478 Size: 492 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item …

New Form 8-K - Cyclacel Pharmaceuticals, Inc. Filed: 2025-07-02 AccNo: 0001641172-25-017479 Size: 328 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits